Arylsulfonamide based matrix metalloprotease inhibitors

Patent metadata

Field	Value
Publication number	US-8975439-B2
Application number	US-201213690274-A
Country	US
Kind code	B2
Filing date	Nov 30, 2012
Priority date	Mar 24, 2008
Publication date	Mar 10, 2015
Grant date	Mar 10, 2015

Abstract

The present invention provides a compound of formula (I):

said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

First claim

We claim:

1. A compound of formula (II)

wherein R′ 1 is selected from cycloakyl, R 5 C(O)—, R 6 SO 2 —, and (R 8 )(R 9 )N—, aryl, heteroaryl, heterocycloalkyl, said aryl, heteroaryl, and heterocycloalkyl are optionally substituted by one or two substituents selected from hydroxy, halo, alkyl, carboxyl, alkoxycarbonyl, and HC(O)—;
wherein R 4 , R 5 , R 6 , R 8 and R…

Assignees

• Novartis Ag

Inventors

• Tommasi Ruben Alberto
• Shultz Michael David
• Mcquire Leslie Wighton
• Rigollier Pascal
• Rogel Olivier
• Ehrhardt Claus

Classifications

• A61P43/00

  Human Necessities · mapped topic

• A61P35/00

  Human Necessities · mapped topic

• A61P35/04

  Human Necessities · mapped topic

• A61P9/04

  Human Necessities · mapped topic

• A61P9/10

  Human Necessities · mapped topic